Mr. Russo brings more than 25 years of diverse industry experience, including in finance and operations for public biotechnology companies, as a sell-side equity research analyst covering biotechnology, and in operations and vaccine manufacturing for a large pharma company.
Company’s novel computationally designed virus-like particle (VLP) technology has the potential to create safe, effective, and durable vaccines against life-threatening
Header one Header two Header three Header four Header five Header six Lorem ipsum dolor sit amet, consectetur adipisicing elit.
Header one Header two Header three Header four Header five Header six Lorem ipsum dolor sit amet, consectetur adipisicing elit.
Header one Header two Header three Header four Header five Header six Lorem ipsum dolor sit amet, consectetur adipisicing elit.
Header one Header two Header three Header four Header five Header six Lorem ipsum dolor sit amet, consectetur adipisicing elit.
Header one Header two Header three Header four Header five Header six Lorem ipsum dolor sit amet, consectetur adipisicing elit.
Header one Header two Header three Header four Header five Header six Lorem ipsum dolor sit amet, consectetur adipisicing elit.
Header one Header two Header three Header four Header five Header six Lorem ipsum dolor sit amet, consectetur adipisicing elit.
Header one Header two Header three Header four Header five Header six Lorem ipsum dolor sit amet, consectetur adipisicing elit.